DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A phase 2 trial of BNT324 and PM8002 in advanced solid tumours, run by DualityBio Inc., now recruiting.
Overview
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors is a phase 2 interventional study registered as NCT06953089 by DualityBio Inc., with 450 participants planned, started 2025-07-18 and due to reach its primary completion in 2030-06-30. Interventions recorded: DB-1311/BNT324, BNT327 and DB-1305/BNT325.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Shares BNT324, Duality Biotherapeutics, PM8002, BioNTech and the tag pipeline.
- TrialA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Shares BNT324, Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Shares Duality Biotherapeutics, PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPM8002 in the Treatment of Patients With Advanced Solid Tumors
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.